Shares of Theravance (THRX) soar over 18% in the post-trading session after coming off an...
Shares of Theravance (THRX) soar over 18% in the post-trading session after coming off an all-day trading halt while awaiting the FDA's decision on its COPD inhaler Breo Ellipta. The stock most recently traded at $33.25, after being halted earlier this morning at $28.01, as the FDA voted solidly in favor of approval.
From other sites
at Nasdaq.com (Mar 25, 2015)
Theravance : GSK and Theravance Update on Outcome of US FDA Advisory Committee on BREO ELLIPTA in Asthmaat 4-traders.com (Mar 25, 2015)
at Zacks.com (Mar 24, 2015)
at Zacks.com (Mar 20, 2015)
at Zacks.com (Mar 11, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs